Trends in Parasitology
ReviewIvermectin: panacea for resource-poor communities?
Section snippets
Need for effective antiparasitics
At a time when the WHO warns that we are facing the daunting future of a world without antibiotics, it is encouraging and comforting to know that some drugs are maintaining, or improving, their impact on public health. Of all the biopharmaceutical products ever discovered, developed, and deployed to maintain or improve human health and welfare, ivermectin is perhaps one of the most diverse, useful, and successful. This was recognised by bestowing of the 2014 Gairdner Global Health Award for the
Ivermectin discovery
In one of the world's most effectual Public/Private Partnerships, in 1973 the Kitasato Institute in Japan joined forces with the Merck Sharpe & Dohme Research Laboratories (MSDRL) in the USA in a search for new and innovative antibiotics. The discovery of the avermectin-producing microorganism, S. avermitilis (Streptomyces avermectinius) at the Kitasato Institute in 1973 was accomplished by a small research group. A unique and structurally very different organism was isolated from a soil sample
Compound characteristics and potential
The avermectins were discovered in 1975 and proved to be broad-spectrum antiparasitic compounds with the ability to kill parasites both inside and outside the body 15, 16, 17, 18, 19. This engendered creation of the term ‘endectocide’ to describe a novel class of chemical compound. They were unprecedented, effective orally, topically or parenterally and at very low doses. They were radically different and lacked cross-resistance with any existing commonly used antiparasitic compounds,
Donated ivermectin
Following unmatched success in the animal health market, Merck scientists soon realised that the anthelmintic potency of ivermectin could help to conquer filarial diseases in humans. Merck joined forces with the WHO, nongovernmental organisations, international donors, governments, and affected communities to drive forward the testing of the drug and registration for large-scale community use [13]. Subsequently, ivermectin (as Mectizan®) was registered for human use by French authorities in
New potential
In addition to the gradual appreciation of the diverse health and socioeconomic benefits that ivermectin use can provide, research is beginning to shed light on the promise of ivermectin and the prospects of it combatting a range of diseases and killing vectors of disease-causing parasites. The following is not the outcome of an exhaustive search of the literature and research under way, it is simply meant to serve as an indicator of the potential that has been identified thus far, and perhaps
Insecticidal
In terms of disease vector control, ivermectin is known to be highly effective in killing a variety of insects 64, 65 A comprehensive examination was carried out testing avermectins against 84 species of insects, covering ten orders, the majority being significant pests of livestock, crops, and of nuisance and health impact in human populations. The avermectins proved toxic to almost all the insects tested, which demonstrated water balance difficulties, as well as disruption of moulting and
Antiviral
For most of the past 40 years, ivermectin was not known to have any antiviral characteristics. Yet recent research has confounded this belief. Ivermectin has been demonstrated to be a broad-spectrum inhibitor of importin α/β nuclear import. Consequently, it has been shown to have potent antiviral activity towards HIV-1 and dengue viruses, both of which are dependent on the importin protein superfamily for several key cellular processes. Ivermectin may be of significance in disrupting HIV-1
Antibacterial
Up until recently, the avermectins were also believed to lack antibacterial activity. However, in 2012, reports emerged that ivermectin was capable of preventing infection of epithelial cells by the bacterial pathogen Chlamydia trachomatis, and to do so at doses that could be used to counter sexually-transmitted or ocular infections [85]. In 2013, researchers further reported that ivermectin appeared to be bactericidal against a range of mycobacterial species, including against multidrug
Anticancer
Owing to its ability to induce membrane hyperpolarisation, ivermectin has now been shown to promote cell death in leukaemia cells, with researchers claiming that ivermectin could be rapidly advanced into clinical trials [88]. The anticancer potential has been supported by recent reports that ivermectin demonstrates activity against chronic lymphocytic leukaemia (CLL) cells and against ME-180 cervical cancer cells [89]. Furthermore, ivermectin has been shown to potentiate doxorubicin-induced
Schistosomiasis
A research collaboration was established between the Kitasato Institute and Fiocruz in Brazil in 2008 to test ivermectin analogues and compounds from the chemical libraries of each institute in screening systems being operated in the two institutions. Promising results were immediately found with regard to the impact of ivermectin on the intermediate host snails responsible for maintaining the schistosomiasis re-infection cycle, offering the prospect of using ivermectin to help control one of
Concluding remarks
A panacea is a Greek-rooted word used to define a remedy for all ills or diseases. Mass administration of ivermectin to all members of poor, polyparasitised communities brings fresh meaning to the concept of a remedy for all, improving health and economic welfare for almost everyone, in both the short and long term (Figure 6).
Ivermectin is recognised as being a comparatively safe drug for human use. In veterinary use, ivermectin can induce severe adverse drug reactions. There are several
References (92)
Ivermectin in onchocerciasis
Lancet
(1982)Ivermectin: 25 years and still going strong
Int. J. Antimicrob. Agents
(2008)22,23-Dihydroavermectin B1a, a new broad-spectrum antiparasitic agent
Br. Vet. J.
(1980)Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm
Lancet
(2006)Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis
Trans. R. Soc. Trop. Med. Hyg.
(2006)Ivermectin as a systemic insecticide
Parasitol. Today
(1989)The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors
Acta Trop.
(2010)Endectocides for malaria control
Trends Parasitol.
(2011)Ivermectin causes Cimex lectularius (Bedbug) morbidity and mortality
J. Emerg. Med.
(2013)Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5: protection against all 4 DENV serotypes by the inhibitor ivermectin
Antiviral Res.
(2013)